Tocilizumab more effective in reducing rheumatoid arthritis symptoms than adalimumab .
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Lancet. 2013 May 4;381(9877):1541-50. doi: 10.1016/S0140-6736(13)60250-0. Epub 2013 Mar 18326 patients with severe rheumatoid arthritis, with whom methotrexate was deemed inappropriate, were randomized to receive tocilizumab intravenously every 4 weeks plus a placebo subcutaneously every 2 weeks for 24 weeks or adalimumab subcutaneously every 2 weeks plus a placebo intravenously every 4 weeks for 24 weeks, in order to compare the safety and efficacy between the two drugs. After the 24 weeks of treatment, the results collected exhibited that the reduction in rheumatoid symptoms was significantly more apparent in patients who received tocilizumab monotherapy, in comparison to the adalimumab monotherapy. Although there were no significant differences between the two groups in regard to incidence of adverse events, it should be noted that the occurrence of abnormalities was higher with the tocilizumab group.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
